Clopiwin 75 Mg. Clopiwin 300 Mg 75 mg. 300 mg FC tablets
PDF Leaflet Revision Date: 12 April 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Secondary reduction of atherothrombotic events in adults.
Dosage (summary)
75 mg once daily; 300 mg loading dose for acute coronary syndrome, then 75 mg daily.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy; not recommended during breastfeeding.
Key Drug Interactions
- Warfarin
- NSAIDs
- SSRIs
- CYP2C19 inhibitors
Contraindications
- Hypersensitivity
- Active bleeding
- Severe liver impairment
- Thrombocytopenia
Common side effects
- Bleeding
- Dyspepsia
- Abdominal pain
- Diarrhoea
Counselling Points
- Report unusual bleeding
- Inform healthcare providers before surgery
- Avoid NSAIDs without consultation
Serious warnings
- Thrombotic thrombocytopenic purpura (TTP)
- Increased bleeding risk
Important Disclaimer
The Clopiwin 75 Mg. Clopiwin 300 Mg 75 mg. 300 mg FC tablets professional information leaflet below is the property of Sanofi-Aventis South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
